Induction of an antigen-specific CTL response by a conformationally biased agonist of human C5a anaphylatoxin as a molecular adjuvant

Journal of Immunology

Volumn 164, Issue 10, 2000, Pages 5492-5498

  Ulrich, J Terry ^a   Cieplak, Witold ^a   Paczkowski, Natalii J ^b   Taylor, Stephen M ^b   Sanderson, Sam D ^c  

^a Corixa ^*  (United States)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPHYLATOXIN; COMPLEMENT COMPONENT C5A; HEPATITIS B SURFACE ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; SPLEEN CELL; T LYMPHOCYTE ACTIVATION;

EID: 0034658633     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.10.5492     Document Type: Article

References (29)

1. Dempsey, P. W., M. E. D. Allison, S. Akkaraju, C. C. Goodnow, and D. T. Fearon. 1996. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271:348.
2. Jacquier-Sarlin, M. R., F. M. Gabert, M.-B. Villiers, and M. G. Colomb. 1995. Modulation of antigen processing and presentation by covalently linked complement C3b fragment. Immunology 84:164.
3. Lou, D., and H. Kohler. 1998. Enhanced molecular mimicry of CEA asing photoaffinity crosslinked C3d peptide. Nat. Biotech. 16:458.
4. Tempero, R. M., M. A. Hollingsworth, M. D. Burdick, A. M. Finch, S. M. Taylor, S. M. Vogen, E. L. Morgan, and S. D. Sanderson. 1997. Molecular adjuvant effects of a conformationally biased agonist of human C5a anaphylatoxin. J. Immunol. 158:1377.
5. Buchner, R. R., S. M. Vogen, W. Fischer, M. L. Thoman, S. D. Sanderson, and H. L. Morgan. 1997. Anti-human κ opioid receptor antibodies. Characterization of site-directed neutralizing antibodies specific for a peptide κR(33-52) derived from the predicted amino terminal region of the human κ receptor. J. Immunol. 158:1670.
6. Sanderson, S. D., L. Kirnarsky, S. A. Sherman, J. A. Ember, A. M. Finch, and S. M. Taylor. 1994. Decapeptide agonists of human C5a: the relationship between conformation and spasmogenic and platelet aggregatory activities. J. Med. Chem. 37:3171.
7. Sanderson, S. D., L. Kirnarsky, S. A. Sherman, S.M. Vogen, O. Prakash, J. A. Ember, A. M. Finch, and S. M. Taylor. 1995. Decapeptide agonists of human C5a: the relationship between conformation and neutrophil response. J. Med. Chem. 38:3669.
8. Finch, A. M., S. M. Vogen, S. A. Sherman, L. Kirnarsky, S. M. Taylor, and S. D. Sanderson. 1997. Biologically active conformer of the effector region of human C5a and modulators effects of N-terminal receptor binding determinants on activity. J. Med. Chem. 40:877.
9. Vogen, S. M., O. Prakash, L. Kirnarsky, S. D. Sanderson, and S. A. Sherman. 1999. Determination of structural elements related to the biological activities of a potent decapeptide agonist of human C5a anaphylatoxin. J. Peptide Res. 54:74.
10. Kawatsu, R., S. D. Sanderson, I. Blanco, N. Kendall, A. M. Finch, S. M. Taylor, and D. Colcher. 1996. Conformationally biased analogs of human C5a mediate changes in vascular permeability. J. Pharmacol. Exp. Therap. 278:432.
11. Wetsel, R. A. 1995. Structure, function, and cellular expression of complement anaphylatoxin receptors. Curr. Opin. Immunol. 7:48.
12. Sozzani, S., F. Sallusto, W. Luini, D. Zhou, L. Piemonti, P. Allavena, J. VanDamme, S. Valitutti, A. Lanzavecchia, and A. Mantovani. 1996. Migration of dendritic cells in response to formyl peptides, C5a, and a distinct set of chemokines. J. Immunol. 155:3292.
13. Van Epps, D. E., S. Simpson, J. G. Bender, and D. E. Chenoweth. 1990. Regulation of C5a and formyl peptide receptor expression on human polymorphonuclear leukocytes. J. Immunol. 144:1062.
14. Schirmbeck, R., K. Melber, T. Mertens, and J. Reimann. 1994. Antibody and cytotoxic T- cell responses to soluble hepatitis B virus (HBV) S antigen in mice: implications for the pathogertesis of HBV-induced hepatitis. J. Virol. 68:1418.
15. Barr, P. J. 1991. Mammalian subtilisins: the long-sought dibasic processing endoproteases. Cell. 66:1.
16. Gordon, V. M., K. R. Klimpel, N. Arora, M. A. Henderson, and S. H. Leppla. 1995. Proteolytic activation of bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases. Infect. Immun. 63:82.
17. Gordon, V. M., and S. H. Leppla. 1994. Proteolytic activation of bacterial toxins: role of bacterial and host cell proteases. Infect. Immun. 62:333.
18. Sarmiento, M., A. L. Glasebrook, and F. W. Fitch. 1980. IgG and IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell-mediated cytolysis in the absence of complement. J. Immunol. 125:2665.
19. Wilde, D. B., P. Marrack, J. Kappler, D. P. Dialynas, and F. W. Fitch. Evidence implicating L3T4 in class II MHC antigen reactivity: monoclonal antibody GK1.5 (anti-L3T4a) blocks class II MHC antigen-specific proliferation, release of lymphokines, and binding by cloned murine helper T lymphocyte lines. J. Immunol. 131:2178.
20. Morgan, E. L., S. D. Sanderson, W. Scholz, D. J. Noonan, W. O. Weigle, and T. E. Hugli. 1992. Identification and characterization of the effector region within human C5a responsible for stimulation of IL-6 synthesis. J. Immunol. 148:3937.
21. Ember, J. A., S. D. Sanderson, T. E. Hugli, and E. L. Morgan. 1994. Induction of IL-8 synthesis from monocytes by human C5a anaphylatoxin. Am. J. Pathol. 144:393.
22. Shen, Z., G. Reznikoff, G. Dranoff, and K. L. Rock. 1997. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J. Immunol. 158:2723.
23. Sigal, L., J. S. Crotty, R. Andino, and K. L. Rock. 1999. Cytotoxic T cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature 398:77.
24. Raychaudhuri, S., and K. L. Rock. 1998. Fully mobilizing host defense: building better vaccines. Nat. Biotech. 16:1025.
25. Goletz, T. J., K. R. Klimpel, N. Arora, S. H. Leppla, J. M. Keith, and J. A. Berzofsky. 1997. Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp 120-anthrax toxin fusion protein. Proc. Natl. Acad. Sci. USA 94:12059.
26. Goletz, T. J., K. R. Klimpel, S. H. Leppla, J. M. Keith, and J. A. Berzofsky. 1997. Delivery of antigens to the MHC class I pathway using bacterial toxins. Hum. Immunol. 54:129.
27. Ballard, J. D., R. J. Collier, and M. N. Starnbach. 1996. Anthrax toxin-mediated delivery of a cytotoxic T cell epitope in vivo. Proc. Natl. Acad. Sci. USA 93: 12531.
28. Doling, A. M., J. D. Ballard, H. Shen, K. M. Krishna, R. Ahmed, R. J. Collier, and M. N. Starnbach. 1999. Cytotoxic T lymphocyte epitopes fused to anthrax toxin induce protective antiviral immunity. Infect. Immun. 67:3290.
29. Gil-Torregrosa, B. C., A. Castano Raul, and M. Del Val. 1998. Major histocompatibility complex class I viral antigen processing in the secretory pathway defined by the trans-Golgi network protease furin. J. Exp. Med. 188:1105.